Glucocorticoid receptor and breast cancer

Breast Cancer Research and Treatment

Volumn 130, Issue 1, 2011, Pages 1-10

  Vilasco, Myriam ^a   Communal, Laudine ^a   Mourra, Najat ^a   Courtin, Aurélie ^a   Forgez, Patricia ^a   Gompel, Anne ^a,b  

^a HÔPITAL SAINT ANTOINE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Apoptosis; Medroxyprogesterone acetate; Normal breast tissue; Progesterone receptor; Proliferation

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DEXAMETHASONE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN DERIVATIVE; GEMCITABINE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; PROGESTERONE; PROMEGESTONE; PROTEIN P53; TRANSCRIPTION FACTOR AP 1;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER MODEL; CELL PROLIFERATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; HUMAN; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOCORTICOIDS; HUMANS; PROGESTINS; RECEPTOR CROSS-TALK; RECEPTORS, ESTROGEN; RECEPTORS, GLUCOCORTICOID; RECEPTORS, PROGESTERONE; RISK;

EID: 79960995168     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1689-6     Document Type: Review

References (114)

1. Jemal A et al (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277-300
2. Kricker A et al (2009) Effects of life event stress and social support on the odds of a > or = 2 cm breast cancer. Cancer Causes Control 20(4):437-447
3. Michael YL et al (2009) Influence of stressors on breast cancer incidence in the women's health initiative. Health Psychol 28(2):137-146
4. Hermes GL et al (2009) Social isolation dysregulates endocrine and behavioral stress while increasing malignant burden of spontaneous mammary tumors. Proc Natl Acad Sci USA 106(52):22393-22398
5. Baschant U, Tuckermann J (2010) The role of the glucocorticoid receptor in inflammation and immunity. J Steroid Biochem Mol Biol 120(2-3):69-75
6. Wintermantel TM et al (2005) The epithelial glucocorticoid receptor is required for the normal timing of cell proliferation during mammary lobuloalveolar development but is dispensable for milk production. Mol Endocrinol 19(2):340-349 (Pubitemid 40223459)
7. Murtagh J et al (2004) Organization of mammary epithelial cells into 3D acinar structures requires glucocorticoid and JNK signaling. J Cell Biol 166(1):133-143 (Pubitemid 38931923)
8. Courtin A et al. (2011) Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells. Breast Cancer Res Treat. PMID: 21336598
9. Perou CM et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747-752
10. Sorlie T et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869-10874 (Pubitemid 32878711)
11. Richardson AL et al (2006) X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9(2):121-132 (Pubitemid 43202662)
12. Teulings FA, van Gilse HA (1977) Demonstration of glucocorticoid receptors in human mammary carcinomas. Horm Res 8(2):107-116 (Pubitemid 8171684)
13. Allegra JC et al (1978) An association between steroid hormone receptors and response to cytotoxic chemotherapy in patients with metastatic breast cancer. Cancer Res 38 (11 Pt 2):4299-4304 (Pubitemid 9054222)
14. Allegra JC et al (1979) Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res 39(5):1447-1454 (Pubitemid 9172656)
15. Moran TJ et al (2000) The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res 60(4):867-872 (Pubitemid 30129517)
16. Schorr K, Furth PA (2000) Induction of bcl-xL expression in mammary epithelial cells is glucocorticoid-dependent but not signal transducer and activator of transcription 5-dependent. Cancer Res 60(21):5950-5953
17. Mikosz CA et al (2001) Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem 276(20):16649-16654
18. Mattern J, Buchler MW, Herr I (2007) Cell cycle arrest by glucocorticoids may protect normal tissue and solid tumors from cancer therapy. Cancer Biol Ther 6(9):1345-1354 (Pubitemid 351590341)
19. Lippman M, Bolan G, Huff K (1976) The effects of glucocorticoids and progesterone on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36(12):4602-4609
20. Osborne CK et al (1979) Direct inhibition of growth and antagonism of insulin action by glucocorticoids in human breast cancer cells in culture. Cancer Res 39 (7 Pt 1):2422-2428 (Pubitemid 9203431)
21. Huff KK et al (1988) Multihormonal regulation of insulin-like growth factor-I-related protein in MCF-7 human breast cancer cells. Mol Endocrinol 2(3):200-208 (Pubitemid 18095168)
22. Harris RA et al (1995) The induction of apoptosis in human mammary luminal epithelial cells by expression of activated c-neu and its abrogation by glucocorticoids. Br J Cancer 72(2):386-392
23. Wu W et al (2004) Microarray analysis reveals glucocorticoid regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res 64(5):1757-1764 (Pubitemid 38428699)
24. Wu W et al (2005) Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. J Biol Chem 280(6):4117-4124 (Pubitemid 40288576)
25. Pang D et al (2006) Dexamethasone decreases xenograft response to Paclitaxel through inhibition of tumor cell apoptosis. Cancer Biol Ther 5(8):933-940
26. Wang H et al (2004) Dexamethasone as a chemoprotectant in cancer chemotherapy: hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine. Cancer Chemother Pharmacol 53(6):459-467 (Pubitemid 38680242)
27. Wang H et al (2007) Dexamethasone as a chemosensitizer for breast cancer chemotherapy: potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics. Int J Oncol 30(4):947-953
28. Zhou J, Cidlowski JA (2005) The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. Steroids 70(5-7):407-417 (Pubitemid 40616039)
29. Miesfeld R et al (1984) Characterization of a steroid hormone receptor gene and mRNA in wild-type and mutant cells. Nature 312(5996):779-781 (Pubitemid 15195930)
30. Govindan MV et al (1985) Cloning of the human glucocorticoid receptor cDNA. Nucleic Acids Res 13(23):8293-8304
31. Galliher-Beckley AJ, Cidlowski JA (2009) Emerging roles of glucocorticoid receptor phosphorylation in modulating glucocorticoid hormone action in health and disease. IUBMB Life 61(10):979-986
32. Bodwell JE et al (1991) Identification of phosphorylated sites in the mouse glucocorticoid receptor. J Biol Chem 266(12):7549-7555 (Pubitemid 21906400)
33. Krstic MD et al (1997) Mitogen-activated and cyclin-dependent protein kinases selectively and differentially modulate transcriptional enhancement by the glucocorticoid receptor. Mol Cell Biol 17(7):3947-3954 (Pubitemid 27281870)
34. Takabe S, Mochizuki K, Goda T (2008) De-phosphorylation of GR at Ser203 in nuclei associates with GR nuclear translocation and GLUT5 gene expression in Caco-2 cells. Arch Biochem Biophys 475(1):1-6
35. Miller AL et al (2005) p38 Mitogen-activated protein kinase (MAPK) is a key mediator in glucocorticoid-induced apoptosis of lymphoid cells: correlation between p38 MAPK activation and site-specific phosphorylation of the human glucocorticoid receptor at serine 211. Mol Endocrinol 19(6):1569-1583 (Pubitemid 41002986)
36. Galliher-Beckley AJ et al (2008) Glycogen synthase kinase 3beta-mediated serine phosphorylation of the human glucocorticoid receptor redirects gene expression profiles. Mol Cell Biol 28(24):7309-7322
37. Itoh M et al (2002) Nuclear export of glucocorticoid receptor is enhanced by c-Jun. N-terminal kinase-mediated phosphorylation. Mol Endocrinol 16(10):2382-2392 (Pubitemid 35155548)
38. Wang Z, Frederick J, Garabedian MJ (2002) Deciphering the phosphorylation "code" of the glucocorticoid receptor in vivo. J Biol Chem 277(29):26573-26580 (Pubitemid 34967155)
39. Chen W et al (2008) Glucocorticoid receptor phosphorylation differentially affects target gene expression. Mol Endocrinol 22(8):1754-1766
40. Blind RD, Garabedian MJ (2008) Differential recruitment of glucocorticoid receptor phospho-isoforms to glucocorticoid induced genes. J Steroid Biochem Mol Biol 109(1-2):150-157
41. Wallace AD, Cidlowski JA (2001) Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids. J Biol Chem 276(46):42714-42721
42. Webster JC et al (1997) Mouse glucocorticoid receptor phosphorylation status influences multiple functions of the receptor protein. J Biol Chem 272(14):9287-9293 (Pubitemid 27154940)
43. Lien HC et al (2006) Differential expression of glucocorticoid receptor in human breast tissues and related neoplasms. J Pathol 209(3):317-327
44. Buxant F, Engohan-Aloghe C, Noel JC (2010) Estrogen receptor, progesterone receptor, and glucocorticoid receptor expression in normal breast tissue, breast in situ carcinoma, and invasive breast cancer. Appl Immunohistochem Mol Morphol 18(3):254-257
45. Horwitz KB, Costlow ME, McGuire WL (1975) MCF-7; a human breast cancer cell line with estrogen, androgen, progesterone, and glucocorticoid receptors. Steroids 26(6):785-795
46. Tronche F et al (1998) Genetic dissection of glucocorticoid receptor function in mice. Curr Opin Genet Dev 8(5):532-538 (Pubitemid 28477355)
47. Reichardt HM et al (1998) DNA binding of the glucocorticoid receptor is not essential for survival. Cell 93(4):531-541 (Pubitemid 28240715)
48. Conde I et al (2008) Glucocorticoid receptor changes its cellular location with breast cancer development. Histol Histopathol 23(1):77-85
49. Belova L et al (2009) Glucocorticoid receptor expression in breast cancer associates with older patient age. Breast Cancer Res Treat 116(3):441-447
50. Chen JQ, Brown TR, Yager JD (2008) Mechanisms of hormone carcinogenesis: evolution of views, role of mitochondria. Adv Exp Med Biol 630:1-18
51. Lillberg K et al (2003) Stressful life events and risk of breast cancer in 10, 808 women: a cohort study. Am J Epidemiol 157(5):415-423 (Pubitemid 36258597)
52. Reiche EM, Nunes SO, Morimoto HK (2004) Stress, depression, the immune system, and cancer. Lancet Oncol 5(10):617-625 (Pubitemid 39303129)
53. Roberts FD et al (1996) Self-reported stress and risk of breast cancer. Cancer 77(6):1089-1093 (Pubitemid 26080898)
54. Kruk J, Aboul-Enein HY (2004) Psychological stress and the risk of breast cancer: a case-control study. Cancer Detect Prev 28(6):399-408 (Pubitemid 39568935)
55. Morrison N, Eisman J (1993) Role of the negative glucocorticoid regulatory element in glucocorticoid repression of the human osteocalcin promoter. J Bone Miner Res 8(8):969-975 (Pubitemid 23219386)
56. De Bosscher K, Vanden Berghe W, Haegeman G (2003) The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 24(4):488-522 (Pubitemid 37059110)
57. Messmer UK et al (2000) Suppression of apoptosis by glucocorticoids in glomerular endothelial cells: effects on proapoptotic pathways. Br J Pharmacol 129(8):1673-1683 (Pubitemid 30219010)
58. Kerppola TK, Luk D, Curran T (1993) Fos is a preferential target of glucocorticoid receptor inhibition of AP-1 activity in vitro. Mol Cell Biol 13(6):3782-3791 (Pubitemid 23157315)
59. Scheinman RI et al (1995) Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Mol Cell Biol 15(2):943-953
60. Imai E et al (1993) Glucocorticoid receptor-cAMP response element-binding protein interaction and the response of the phosphoenolpyruvate carboxykinase gene to glucocorticoids. J Biol Chem 268(8):5353-5356 (Pubitemid 23090847)
61. Lin A, Karin M (2003) NF-kappaB in cancer: a marked target. Semin Cancer Biol 13(2):107-114
62. Herr I et al (2007) Regulation of differential pro-and antiapoptotic signaling by glucocorticoids. Apoptosis 12(2):271-291 (Pubitemid 46169909)
63. Feng Z et al (1995) Glucocorticoid and progesterone inhibit involution and programmed cell death in the mouse mammary gland. J Cell Biol 131(4):1095-1103
64. Diamond MI et al (1990) Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. Science 249(4974):1266-1272
65. Shaulian E, Karin M (2002) AP-1 as a regulator of cell life and death. Nat Cell Biol 4(5):E131-E136 (Pubitemid 34521026)
66. Lu A et al (2002) Blockade of AP1 transactivation abrogates the abnormal expression of breast cancer-specific gene 1 in breast cancer cells. J Biol Chem 277(35):31364-31372 (Pubitemid 34968935)
67. Bamberger AM et al (1999) Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive tumor phenotype. Int J Cancer 84(5):533-538
68. Milde-Langosch K (2005) The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer 41(16):2449-2461 (Pubitemid 41540622)
69. Ozaki T, Nakagawara A (2011) p53: the attractive tumor suppressor in the cancer research field. J Biomed Biotechnol 2011:603925
70. Sengupta S, Wasylyk B (2001) Ligand-dependent interaction of the glucocorticoid receptor with p53 enhances their degradation by Hdm2. Genes Dev 15(18):2367-2380 (Pubitemid 32899741)
71. Sengupta S et al (2000) Negative cross-talk between p53 and the glucocorticoid receptor and its role in neuroblastoma cells. EMBO J 19(22):6051-6064
72. Moll UM, Riou G, Levine AJ (1992) Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 89(15):7262-7266
73. Maiyar AC et al (1997) Repression of glucocorticoid receptor transactivation and DNA binding of a glucocorticoid response element within the serum/glucocorticoid-inducible protein kinase (sgk) gene promoter by the p53 tumor suppressor protein. Mol Endocrinol 11(3):312-329 (Pubitemid 27106327)
74. Maiyar AC et al (1996) p53 stimulates promoter activity of the sgk, serum/glucocorticoid-inducible serine/threonine protein kinase gene in rodent mammary epithelial cells. J Biol Chem 271(21):12414-12422 (Pubitemid 26160910)
75. Goya L et al (1993) Glucocorticoids induce a G1/G0 cell cycle arrest of Con8 rat mammary tumor cells that is synchronously reversed by steroid withdrawal or addition of transforming growth factor-alpha. Mol Endocrinol 7(9):1121-1132 (Pubitemid 23285271)
76. Urban G et al (2003) Identification of a functional link for the p53 tumor suppressor protein in dexamethasone-induced growth suppression. J Biol Chem 278(11):9747-9753 (Pubitemid 36800473)
77. Gutierrez MC et al (2005) Molecular changes in tamoxifenresistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 23(11):2469-2476 (Pubitemid 47050837)
78. Whyte J et al (2009) Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development. Breast Cancer Res 11(5):209
79. Kee TH, Vit P, Melendez AJ (2005) Sphingosine kinase signalling in immune cells. Clin Exp Pharmacol Physiol 32(3):153-161 (Pubitemid 40387111)
80. Ewing TM et al (1989) Regulation of epidermal growth factor receptor by progestins and glucocorticoids in human breast cancer cell lines. Int J Cancer 44(4):744-752 (Pubitemid 19258755)
81. Doll F, Pfeilschifter J, Huwiler A (2005) The epidermal growth factor stimulates sphingosine kinase-1 expression and activity in the human mammary carcinoma cell line MCF7. Biochim Biophys Acta 1738(1-3):72-81 (Pubitemid 43122132)
82. Grunberg SM et al (2009) Effectiveness of a single-day threedrug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer 17(5):589-594
83. Herrington JD, Jaskiewicz AD, Song J (2008) Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 112(9):2080-2087 (Pubitemid 351574085)
84. Lu YS et al (2005) Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptors. World J Gastroenterol 11(40):6373-6380
85. Wang H et al (2004) Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin Cancer Res 10(5):1633-1644 (Pubitemid 38435553)
86. Balkwill F (2002) Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13(2):135-141 (Pubitemid 34229388)
87. Loda M et al (1996) Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. Am J Pathol 149(5):1553-1564 (Pubitemid 26363962)
88. Magi-Galluzzi C et al (1997) Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. Lab Invest 76(1):37-51 (Pubitemid 27058196)
89. Braunschweiger PG, Schiffer LM (1981) Antiproliferative effects of corticosteroids in C3H/HeJ mammary tumors and implications for sequential combination chemotherapy. Cancer Res 41 (9 Pt 1):3324-3330 (Pubitemid 11063596)
90. Stuhr LE et al (2006) High-dose, short-term, anti-inflammatory treatment with dexamethasone reduces growth and augments the effects of 5-fluorouracil on dimethyl-alpha-benzanthraceneinduced mammary tumors in rats. Scand J Clin Lab Invest 66(6):477-486 (Pubitemid 44454444)
91. Hall RE et al (1990) Steroid hormone receptor gene expression in human breast cancer cells: inverse relationship between oestrogen and glucocorticoid receptor messenger RNA levels. Int J Cancer 46(6):1081-1087
92. De Fazio A et al (1997) Antisense estrogen receptor RNA expression increases epidermal growth factor receptor gene expression in breast cancer cells. Cell Growth Differ 8(8):903-911 (Pubitemid 27355463)
93. Krishnan AV, Swami S, Feldman D (2001) Estradiol inhibits glucocorticoid receptor expression and induces glucocorticoid resistance in MCF-7 human breast cancer cells. J Steroid Biochem Mol Biol 77(1):29-37 (Pubitemid 32455350)
94. Zhang Y et al (2009) Estrogen inhibits glucocorticoid action via protein phosphatase 5 (PP5)-mediated glucocorticoid receptor dephosphorylation. J Biol Chem 284(36):24542-24552
95. Gong H et al (2008) Glucocorticoids antagonize estrogens by glucocorticoid receptor-mediated activation of estrogen sulfotransferase. Cancer Res 68(18):7386-7393
96. Allegra JC et al (1979) Relationship between the progesterone, androgen, and glucocorticoid receptor and response rate to endocrine therapy in metastatic breast cancer. Cancer Res 39 (6 Pt 1):1973-1979 (Pubitemid 9184986)
97. Wan Y et al (2001) Separable features of the ligand-binding domain determine the differential subcellular localization and ligand-binding specificity of glucocorticoid receptor and progesterone receptor. Mol Endocrinol 15(1):17-31 (Pubitemid 32156038)
98. Deroo BJ, Archer TK (2001) Glucocorticoid receptor-mediated chromatin remodeling in vivo. Oncogene 20(24):3039-3046 (Pubitemid 32553558)
99. Li X et al (2003) Progesterone and glucocorticoid receptors recruit distinct coactivator complexes and promote distinct patterns of local chromatin modification. Mol Cell Biol 23(11):3763-3773 (Pubitemid 36597457)
100. van den Berg HW, Lynch M, Martin JH (1993) The relationship between affinity of progestins and antiprogestins for the progesterone receptor in breast cancer cells (ZR-PR-LT) and ability to down-regulate the receptor: evidence for heterospecific receptor modulation via the glucocorticoid receptor. Eur J Cancer 29 A (12):1771-1775 (Pubitemid 23275887)
101. Wan Y, Nordeen SK (2003) Overlapping but distinct profiles of gene expression elicited by glucocorticoids and progestins. Recent Prog Horm Res 58:199-226 (Pubitemid 37339310)
102. Buser AC et al (2007) Progesterone receptor repression of prolactin/signal transducer and activator of transcription 5-mediated transcription of the beta-casein gene in mammary epithelial cells. Mol Endocrinol 21(1):106-125 (Pubitemid 46043298)
103. Quirk SJ et al (1985) Progestins specifically suppress alphalactalbumin synthesis and secretion. J Steroid Biochem 23(6 A):901-905 (Pubitemid 16152408)
104. Wiegratz I, Kuhl H (2004) Progestogen therapies: differences in clinical effects? Trends Endocrinol Metab 15(6):277-285 (Pubitemid 39044202)
105. Poulin R et al (1991) Multiple actions of synthetic " progestins" on the growth of ZR-75-1 human breast cancer cells: an in vitro model for the simultaneous assay of androgen, progestin, estrogen, and glucocorticoid agonistic and antagonistic activities of steroids. Breast Cancer Res Treat 17(3):197-210
106. Kontula K et al (1983) Binding of progestins to the glucocorticoid receptor. Correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes. Biochem Pharmacol 32(9):1511-1518 (Pubitemid 13096010)
107. Parazzini F et al (1993) Treatment with tamoxifen and progestins for metastatic breast cancer in postmenopausal women: a quantitative review of published randomized clinical trials. Oncology 50(6):483-489 (Pubitemid 23323720)
108. Willemse PH et al (1990) Adrenal steroids as parameters of the bioavailability of MA and MPA. Eur J Cancer 26(3):359-362 (Pubitemid 20149165)
109. Foidart JM et al (2007) Hormone therapy and breast cancer risk. Climacteric 10 (Suppl 2):54-61
110. Chlebowski RT et al (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304(15):1684-1692
111. Hofseth LJ et al (1999) Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 84(12):4559-4565
112. Wood CE et al (2007) Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat 101(2):125-134 (Pubitemid 46115419)
113. Murkes D et al (2011) Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women. Fertil Steril 95(3):1188-1191
114. Wood CE, Register TC, Cline JM (2009) Transcriptional profiles of progestogen effects in the postmenopausal breast. Breast Cancer Res Treat 114(2):233-242